mutations supplied The point that, as spelled out below, CLL therapy relies over the presence or absence of such mutations. The present consensus is, other than clonal mutations, subclonal mutations with a variant allelic frequency starting from five to ten% (and therefore beneath the edge of detection by regular molecular tactics) may be claimed,